Keros Therapeutics financials
$11.19−0.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $367.0K | $385.0K | $14.3M | $18.2M | $211.2M | $3.0M | $388.0K | $37.0K | $83.0K | $143.0K | $8.0K |
| Gross profit | $0.00 | $367.0K | $385.0K | $14.3M | $18.2M | $211.2M | $3.0M | $388.0K | $37.0K | $83.0K | $143.0K | $8.0K |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$30.9M | -$25.9M | -$29.3M | -$15.4M | -$39.8M | $152.0M | -$53.3M | -$58.7M | -$50.4M | -$48.5M | -$44.1M | -$43.3M |
| Net income | -$28.7M | -$23.7M | -$23.5M | -$7.3M | -$30.7M | $148.5M | -$46.0M | -$53.0M | -$45.3M | -$43.1M | -$40.2M | -$39.4M |
| Net margin | — | −6459.9% | −6093.8% | −51.0% | −169.0% | 70.3% | −1513.0% | −13648.5% | −122316.2% | −51944.6% | −28142.0% | −493000.0% |
| Diluted EPS | $-1.45 | $-1.21 | $-0.80 | $-0.18 | $-0.76 | $3.62 | $-1.14 | $-1.41 | $-1.25 | $-1.21 | $-1.33 | $-1.33 |
| EBITDA | -$30.5M | -$25.5M | -$28.9M | -$15.0M | -$39.4M | $152.4M | -$52.9M | -$58.3M | -$50.1M | -$48.2M | -$43.8M | -$43.1M |
| Operating cash flow | -$20.4M | -$3.5M | -$27.3M | $3.2M | -$29.6M | $161.2M | -$46.0M | -$30.5M | -$39.8M | -$44.6M | -$25.5M | -$34.0M |
| Free cash flow | -$20.6M | -$3.6M | -$27.4M | $3.1M | -$30.3M | $160.6M | -$46.3M | -$30.9M | -$40.1M | -$45.5M | -$26.0M | -$34.5M |
| Diluted shares | 19.8M | 19.6M | 29.2M | 40.6M | 40.6M | 41.0M | 40.4M | 37.6M | 36.1M | 35.7M | 30.1M | 29.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $257.6M | $281.5M | $287.4M | $693.5M | $690.2M | $720.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $287.6M | $312.3M | $338.0M | $742.8M | $757.2M | $784.6M |
| Total liabilities | $25.3M | $26.7M | $34.9M | $39.2M | $50.4M | $55.7M |
| Shareholders' equity | $262.3M | $285.6M | $303.1M | $703.6M | $706.7M | $728.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology